Volume 90 Issue 18 | p. 10 | News of The Week
Issue Date: April 30, 2012

AstraZeneca To Buy Ardea

Pharmaceuticals: Small-molecule drug firm will bring a late-stage gout treatment
Department: Business
Keywords: pharmaceuticals, acquisitions, gout

AstraZeneca has struck a deal to buy the small-molecule drug company Ardea Biosciences for $1.26 billion. San Diego-based Ardea has three compounds in development: two that target gout and one in the oncology area.

Ardea’s most advanced candidate, lesinurad, is a selective inhibitor of URAT1, a transporter in kidney cells that regulates uric acid excretion from the body. Chronic hyperuricemia, or abnormally elevated uric acid levels in the blood, is a symptom . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society